Hans Hammers
@HHammersMD
Medical oncologist with focus on kidney cancer, immunotherapies and the tumor microenvironment. Views expressed are my own. #kidneycancer #immunotherapy
Great meeting!! Thank you everyone and in particular to our patient volunteers! Save the date for July 23/24 2026! #KCRS25 @kidneycan
And that is wrap for #KCRS2025 @HHammersMD @advocatekidneys @kidneycan
Thank you @CJSTRAV3 @kidneycan
@CJSTRAV3 Inspirational words from a patient, advocate, and research collaborator at #KCRS25 Patients are not just participants they are partners in discovery and change. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre…
Look at some of the impact of DOD CDMRP funding. @BraunMDPhD is presenting the personalized vaccine in RCC published in @Nature. Please restore funding. It went from $50 Million to $0 Dollars. We have not solved cancer yet! @kidneycan #KCRS25
“Invest in PEOPLE.” Powerful reminder from @KimrynRathmell at #KCRS25 Because curing kidney cancer starts with empowering the next generation. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre @AlbigesL @MikeSerzanMD…
#KCRS2025 Great discussion on decentralized study design for rare histologies / non-clear cell RCC. We need to accelerate breakthroughs AND break down unnecessary regulatory barriers to allow Telehealth across state lines. NATIONAL MEDICAL LICENSES!! @kidneycan
Can’t wait! Amazing faculty, clinicians, scientists, patients and advocates. Always the highlight for me. #KCRS25 @kidneycan
Just three days until KCRS 2025! We’re getting ready to welcome researchers, clinicians, advocates, and patients from around the world to explore the future of #KidneyCancer research. #KCRS25 #AcceleratingCures
Let us do this ! #KCRS2025 @kidneycan @advocatekidneys @DrRanaMcKay @HHammersMD @montypal @arihakimi @tompowles1
Just three days until KCRS 2025! We’re getting ready to welcome researchers, clinicians, advocates, and patients from around the world to explore the future of #KidneyCancer research. #KCRS25 #AcceleratingCures
Please join us free from all over the world! #KCRS25 #kidneycancer
Excited for #KCRS25 where kidney cancer minds meet, share, and spark new ideas! @oncoalert @DrChoueiri @CParkMD @HHammersMD @montypal @AlbigesL @yekeduz_emre @kidneycan @IKCCorg #Boston
What does real-world kidney cancer care look like in 2025? Dr. @HHammersMD will walk through it in a case-based format at #WorldGU25—part of our interactive session on Real-World Management & Therapeutic Interventions in GU Cancers. Aug 21–23 | Nashville, TN | Up to 11.75 #CE…
I wish we would take a hard look at the future and invest into 🇺🇸 leadership. Let’s leave politics behind. There are ultimate truths - let’s follow them.
Solar power in China will exceed ALL sources of electricity combined in the USA in 3 to 4 years. Wake up call.
Agree!! Brilliant and so deserved. Congrats !
Brilliant appointment! One of the very best people. Smart, collegiate and a great friend. Well done Samra and all the Turajlic family! @DrChoueiri @montypal @HHammersMD @AlbigesL @neerajaiims
Always fun to discuss with my colleagues! @high5md
RCC updates from #ASCO25 are live on high5oncologyTV 🧬 Summarized in 100 seconds and thoroughly discussed by experts: high5oncology.tv/meeting-covera… @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini #KidneyCancer #RCC #RenalCellCarcinoma #ASCO2025…
Will be fun !! #WorldGU25
🔥 Ready for next-level RCC insights? Hot off #ASCO25, Dr. @HHammersMD will unpack kidney cancer advances at #WorldGU25. Join us in Nashville, TN, Aug 21–23 for this #CE-accredited event. Register now: hubs.la/Q03qd0T_0 #KidneyCancer #GUOncology #CME
I agree. TKI/HIF2 vs potent TKI like Cabo will be close… Let’s see, but it’s becoming clear that “synergy” is unlikely
#ASCO25 HIF inhibitor combination results. Shown below is single agent Cabo and Belzu for reference, and published HIF-based combo data. *ORR marginally higher *PFS longer but endpoint not reliable in a single-arm trial *Phase 3 trials are planned. Beating TKI may be challenging
Targeting HIF-2α: A new era in RCC! Presented by Dr. Rana McKay. #ASCO25 #cancer #oncology @oncoalert @ASCO @medicalwatchBC @DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal…
💫State of Science Novel Dx/Tx RCC & UC #ASCO25 👉Dr @DrRanaMcKay presenting Targeting #HIF2α: A New Frontier in Renal Cell Cancer Therapy 🧬 HIF2 expression is prognostic! mOS (92.6 vs 68.1mo HR 0.61, 0.51-0.73) Abst4543 @YuWeiChenMD 💊 Belzutifan initially approved in…
Will be a great meeting! Consider joining us!
📣 The #WorldGU25 faculty list is live! Over 60 GU oncology leaders—from academic giants to real-world clinical experts—are joining us in Nashville, TN, Aug 21–23. Chaired by Drs. @CaPsurvivorship & @Daniel_J_George. CE-accredited. View the faculty & register today:…
#ASCO25 kicks off the conversation. #WorldGU25 delivers focused updates on bladder, prostate, and kidney cancers. With esteemed faculty like Drs. @MattMilowsky, @MRHarrisonMD, @JCensits, @BGarmezy, @DrDarrenFeldman, and nearly 60 other multidisciplinary thought leaders, this…
Looking forward to lively exchanges and discussions. Hopefully lots of practical insights! #kidneycancer
Join your peers and colleagues for thoughtful discussions, practical insights, and a shared commitment to better outcomes. @brian_rini @HHammersMD @AbhiTrip87
Incredibly important. Don’t undertreat bone Mets even for pain control !
🚀 New in @JCO_ASCO - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048